Cargando…
Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
OBJECTIVE: We aimed to examine the association between bone morphogenetic protein-9 (BMP-9) and type 2 diabetes mellitus (T2DM) in conjunction with non-alcoholic fatty liver disease (NAFLD) and insulin resistance (IR) and to identify evidence supporting the potential role of BMP-9 in the clinical pr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741848/ https://www.ncbi.nlm.nih.gov/pubmed/36514745 http://dx.doi.org/10.2147/IJGM.S385513 |
_version_ | 1784848403619905536 |
---|---|
author | Hao, Jianan Wang, Yichao Huo, Lijing Sun, Tiantian Zhen, Yunfeng Gao, Zhe Chen, Shuchun Ren, Luping |
author_facet | Hao, Jianan Wang, Yichao Huo, Lijing Sun, Tiantian Zhen, Yunfeng Gao, Zhe Chen, Shuchun Ren, Luping |
author_sort | Hao, Jianan |
collection | PubMed |
description | OBJECTIVE: We aimed to examine the association between bone morphogenetic protein-9 (BMP-9) and type 2 diabetes mellitus (T2DM) in conjunction with non-alcoholic fatty liver disease (NAFLD) and insulin resistance (IR) and to identify evidence supporting the potential role of BMP-9 in the clinical prevention and treatment of T2DM in conjunction with NAFLD. METHODS: One hundred and twenty subjects were included in this study. We sorted all of the subjects into four groups of equal size (n=30 each). A trained expert assessed the height, weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP) of the subjects and computed the body mass index (BMI). All subjects had their fasting blood glucose (FBG), fasting insulin (FINS), serum BMP-9, and biochemical indices assessed. RESULTS: Significant variations were observed in BMI, SBP, DBP, ALT, TC, TG, HDL-C, LDL-C, ApoB, FBG, FINS, HOMA-IR, and serum BMP-9 among the four groups (P<0.05). The level of serum BMP-9 was positively correlated with HDL-C, while the level of serum BMP-9 was negatively correlated with BMI, SBP, DBP, ALT, TC, TG, LDL-C, FBG, FINS, and HOMA-IR. Multiple stepwise regression analyses revealed that FINS, LDL-C, HDL-C, and BMI were independent factors impacting serum BMP-9 levels (P<0.05). Logistic regression analyses revealed that BMP-9 was a protective factor for T2DM paired with NAFLD, while HOMA-IR was a risk factor. CONCLUSION: Serum BMP-9 levels are significantly lower in the T2DM+NAFLD group when compared to other groups, and BMP-9 is an independent risk factor for T2DM paired with NAFLD. |
format | Online Article Text |
id | pubmed-9741848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-97418482022-12-12 Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Hao, Jianan Wang, Yichao Huo, Lijing Sun, Tiantian Zhen, Yunfeng Gao, Zhe Chen, Shuchun Ren, Luping Int J Gen Med Original Research OBJECTIVE: We aimed to examine the association between bone morphogenetic protein-9 (BMP-9) and type 2 diabetes mellitus (T2DM) in conjunction with non-alcoholic fatty liver disease (NAFLD) and insulin resistance (IR) and to identify evidence supporting the potential role of BMP-9 in the clinical prevention and treatment of T2DM in conjunction with NAFLD. METHODS: One hundred and twenty subjects were included in this study. We sorted all of the subjects into four groups of equal size (n=30 each). A trained expert assessed the height, weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP) of the subjects and computed the body mass index (BMI). All subjects had their fasting blood glucose (FBG), fasting insulin (FINS), serum BMP-9, and biochemical indices assessed. RESULTS: Significant variations were observed in BMI, SBP, DBP, ALT, TC, TG, HDL-C, LDL-C, ApoB, FBG, FINS, HOMA-IR, and serum BMP-9 among the four groups (P<0.05). The level of serum BMP-9 was positively correlated with HDL-C, while the level of serum BMP-9 was negatively correlated with BMI, SBP, DBP, ALT, TC, TG, LDL-C, FBG, FINS, and HOMA-IR. Multiple stepwise regression analyses revealed that FINS, LDL-C, HDL-C, and BMI were independent factors impacting serum BMP-9 levels (P<0.05). Logistic regression analyses revealed that BMP-9 was a protective factor for T2DM paired with NAFLD, while HOMA-IR was a risk factor. CONCLUSION: Serum BMP-9 levels are significantly lower in the T2DM+NAFLD group when compared to other groups, and BMP-9 is an independent risk factor for T2DM paired with NAFLD. Dove 2022-12-07 /pmc/articles/PMC9741848/ /pubmed/36514745 http://dx.doi.org/10.2147/IJGM.S385513 Text en © 2022 Hao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Hao, Jianan Wang, Yichao Huo, Lijing Sun, Tiantian Zhen, Yunfeng Gao, Zhe Chen, Shuchun Ren, Luping Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease |
title | Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease |
title_full | Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease |
title_fullStr | Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease |
title_full_unstemmed | Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease |
title_short | Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease |
title_sort | circulating bone morphogenetic protein-9 is decreased in patients with type 2 diabetes and non-alcoholic fatty liver disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741848/ https://www.ncbi.nlm.nih.gov/pubmed/36514745 http://dx.doi.org/10.2147/IJGM.S385513 |
work_keys_str_mv | AT haojianan circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease AT wangyichao circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease AT huolijing circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease AT suntiantian circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease AT zhenyunfeng circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease AT gaozhe circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease AT chenshuchun circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease AT renluping circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease |